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1. INTRODUCTION {#cas13626-sec-0001}
===============

According to its pathological classification, non‐small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Despite the development of molecular target drugs in recent years, the long‐term survival rate remains poor. Thus, continued efforts are needed to understand the molecular mechanisms of lung cancer progression for the development of new targeted therapies.

Transforming growth factor‐β (TGF‐β) regulates various developmental and pathological processes. The receptor‐regulated class of Smad proteins (R‐Smads), such as Smad2 and Smad3, are directly phosphorylated by type I TGF‐β receptor kinase.[1](#cas13626-bib-0001){ref-type="ref"} Phosphorylated R‐Smads then form complexes with Smad4 and translocate to the nucleus. In the nucleus, Smad complexes act as a transcription factor to regulate the expression of target genes. Previous studies have shown that signal‐induced cytoplasmic‐to‐nuclear translocation of Smad3 is supported by multiple factors, including importin, exportin, and a direct interaction with nucleoporins. In particular, in the nuclear import step, previous studies revealed that TGF‐β‐induced Smad3 phosphorylation enhances its interaction with importin β1 and its nuclear accumulation in a Ran‐dependent manner.[2](#cas13626-bib-0002){ref-type="ref"}, [3](#cas13626-bib-0003){ref-type="ref"} In addition, another group recently showed that the nuclear import of Smad1 and Smad2/3 is mediated by importin 7 and 8.[4](#cas13626-bib-0004){ref-type="ref"}

In cancer cells, TGF‐β paradoxically exerts both tumor‐suppressive and tumor‐promoting effects. In the early stage of cancer, TGF‐β promotes cell cycle arrest and apoptosis; however, in advanced stages, TGF‐β mediates tumor progression by promoting cell motility, invasive ability and epithelial‐to‐mesenchymal transition (EMT).[5](#cas13626-bib-0005){ref-type="ref"}, [6](#cas13626-bib-0006){ref-type="ref"} EMT is a dynamic process that mediates normal development. However, EMT also occurs in pathological contexts in tumor invasion and metastasis. During EMT, polarized epithelial cells alter their morphology and acquire the characteristics of mesenchymal cells. TGF‐β is a major inducer of EMT,[7](#cas13626-bib-0007){ref-type="ref"} and upon TGF‐β treatment, epithelial cells lose cell‐cell adhesion, change their morphology to an elongated spindle shape, and exhibit increased motility and invasiveness. EMT is also associated with resistance to apoptosis and chemotherapy. Therefore, a better understanding of TGF‐β signaling and EMT is important for the development of new therapeutic strategies.

An increasing number of studies have demonstrated the importance of long non‐coding RNAs (lncRNAs), which are RNAs longer than 200 bases that lack protein coding ability.[8](#cas13626-bib-0008){ref-type="ref"} LncRNAs were previously thought to be transcriptional junk, but an increasing volume of evidence describes their functions. Although the biological roles of the majority of lncRNAs remain unexplored, some have been suggested to act as guides, decoys or scaffolds. Mechanistically, cytoplasmic lncRNAs are known to modulate the activity or abundance of their interacting proteins or microRNAs (miRNAs). Several studies have shown that some lncRNAs play roles in tumor progression, invasion and metastasis.[9](#cas13626-bib-0009){ref-type="ref"}, [10](#cas13626-bib-0010){ref-type="ref"}, [11](#cas13626-bib-0011){ref-type="ref"} In particular, some lncRNAs are thought to be involved in TGF‐β signaling and TGF‐β‐induced EMT.[12](#cas13626-bib-0012){ref-type="ref"}, [13](#cas13626-bib-0013){ref-type="ref"}, [14](#cas13626-bib-0014){ref-type="ref"}, [15](#cas13626-bib-0015){ref-type="ref"}, [16](#cas13626-bib-0016){ref-type="ref"} However, the detailed molecular mechanisms of these lncRNAs are not fully understood.

Recently, the functions of a novel cytoplasmic lncRNA, *NORAD* (also known as LINC00657 or LOC647979), have been characterized. *NORAD* is expressed at 500‐1000 copies per cell, and it binds to and suppresses the activity of Pumilio proteins that bind specific mRNAs at their consensus sequence for downregulation. *NORAD* thus upregulates target transcripts of Pumilio proteins and plays a role in genomic stability.[17](#cas13626-bib-0017){ref-type="ref"}, [18](#cas13626-bib-0018){ref-type="ref"} In addition, *NORAD* is reported to be an oncogene, as its expression is associated with poor prognosis in breast and pancreatic cancer patients.[19](#cas13626-bib-0019){ref-type="ref"}, [20](#cas13626-bib-0020){ref-type="ref"} In pancreatic cancer cells, *NORAD* has been demonstrated to promote EMT and metastasis; however, the mechanisms underlying these events are not fully understood. In this study, we found that *NORAD* regulates TGF‐β signaling and TGF‐β‐induced EMT‐like phenotype independently of the involvement of Pumilio proteins in A549 lung adenocarcinoma cells. Our data reveal that *NORAD* regulates TGF‐β signaling by mediating the signal‐induced nuclear translocation of Smad complexes. Our findings may provide a potential molecular target for NSCLC.

2. MATERIALS AND METHODS {#cas13626-sec-0002}
========================

2.1. Cell culture {#cas13626-sec-0003}
-----------------

A549 cells were obtained from the JCRB cell bank. A549 cells were cultured in DMEM (\#11965; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (\#SH30910.03; Thermo Fisher Scientific), 100 U/mL penicillin G and 100 μg/mL streptomycin. Cells were cultured in a humidified atmosphere of 5% CO~2~ at 37°C.

2.2. Reagents and antibodies {#cas13626-sec-0004}
----------------------------

Recombinant TGF‐β (TGF‐β3) was purchased from R&D Systems (Minneapolis, MN, USA). Phalloidin‐tetramethylrhodamine B isothiocyanate (\#P1951) was obtained from Sigma‐Aldrich (St. Louis, MO, USA). Antibodies against Smad2 (\#ab33875) and Smad3 (\#ab40854) were purchased from Abcam (Cambridge, UK). Anti‐phospho‐Smad3 (Ser423/425; \#9520) antibody was purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody against Smad2/3 (\#610843) was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Anti‐HDAC1 (\#2E10) and phospho‐Smad2 (Ser465/467; \#04‐953) antibodies were obtained from Merck Millipore (Darmstadt, Germany). Antibody against c‐Myc (\#017‐21871) was obtained from Wako Pure Chemical Industries (Osaka, Japan). Antibodies against FLAG (M2; \#F3165) and α‐tubulin (\#T6199) were obtained from Sigma‐Aldrich.

2.3. Plasmids {#cas13626-sec-0005}
-------------

Plasmids encoding human PUM1, *NORAD*, Smad3 and importin β1 were constructed by PCR amplification. Fragments were subcloned into pcDNA3‐FLAG vector (PUM1 and importin β1), CSII‐CMV‐RfA (*NORAD*) or pcDNA3‐6xMyc vector (Smad3). All cDNAs were verified by sequencing.

2.4. Lentivirus production and infection {#cas13626-sec-0006}
----------------------------------------

Lentiviral shRNA expression vectors were generated as described previously[21](#cas13626-bib-0021){ref-type="ref"} using the following oligonucleotides: \#1, forward: GATCCCC GCGGTTGGTCTTCATTCTACCACGTGTGCTGTCCGTGGTAGAATGAAGACCAACCGC TTTTTGGAAAT, reverse: CTAGATTT CCAAAAA GCGGTTGGTCTTCATTCTACCACGGACAGCACACGTGGTAGAATGAAGACCAACCGC GGG; \#2, forward: GATCCCC GCTAGTATCTCCATATCTAGAACGTGTGCTGTCCGTTCTAGATATGGAGATACTAGC TTTTTGGAAAT, reverse: CTAGATTTCCAAAAA GCTAGTATCTCCATATCTAGAACGGACAGCACACGTTCTAGATATGGAGATACTAGC GGG.

Lentiviral expression vectors were obtained from Dr Hiroyuki Miyoshi (RIKEN BioResource Center; current address Keio University, Tokyo, Japan). shRNAs were transferred into the lentivirus vector CS‐RfA‐EG through the pENTER‐4H1 vector. To produce lentivirus, HEK293FT cells were co‐transfected with the vector constructs CS‐RfA‐EG (for shRNAs), CSII‐CMV‐RfA (for *NORAD* expression), pCMV‐VSV‐G‐RSV‐Rev and pCAG‐HIVgp. Virus was collected, concentrated using the Lenti‐X Concentrator (Takara Bio, Shiga, Japan), and used to infect A549 cells.

2.5. Transfection of cDNA {#cas13626-sec-0007}
-------------------------

Transient transfection into cells was performed using Lipofectamine 3000 Reagent (Thermo Fisher Scientific), as recommended by the manufacturer\'s protocol.

2.6. Immunoblotting {#cas13626-sec-0008}
-------------------

Cells were rinsed with ice‐cold PBS and lysed with lysis buffer (1% NP‐40, 150 mmol/L NaCl, 20 mmol/L Tris‐HCl \[pH 7.5\] and cOmplete EDTA‐free protease inhibitor \[Roche Diagnostics, Basel, Switzerland\]). After centrifugation at 20 400 *g*) and 4°C for 10 min, protein concentrations were estimated using the BCA Protein Assay Kit (Thermo Fisher Scientific). Total cell lysates were subjected to SDS polyacrylamide gel electrophoresis and transferred to Fluoro Trans W membranes (Pall, Port Washington, NY, USA). Immunoblotting was carried out using the indicated antibodies, and imaging was performed with an LAS‐4000 lumino‐image analyzer (FUJIFILM, Tokyo, Japan).

2.7. Immunoprecipitation {#cas13626-sec-0009}
------------------------

Cultured cells were lysed as described above. Immunoprecipitation was performed as previously described.[22](#cas13626-bib-0022){ref-type="ref"}

2.8. RNA extraction and quantitative RT‐PCR {#cas13626-sec-0010}
-------------------------------------------

For mRNA detection, total RNA was extracted with the RNeasy Mini Kit (QIAGEN, Dusseldorf, Germany). First‐strand cDNAs were synthesized using PrimeScript II reverse transcriptase (Takara Bio). Quantitative RT‐PCR was performed with the StepOnePlus Real‐Time PCR System (Thermo Fisher Scientific). All samples were run in duplicate, and results were averaged and normalized to the expression of *GAPDH* (glyceraldehyde‐3‐phosphate dehydrogenase). Primer sequences are shown in Table [S1](#cas13626-sup-0002){ref-type="supplementary-material"}.

2.9. Chamber migration assay {#cas13626-sec-0011}
----------------------------

The migration assay was performed as described previously.[23](#cas13626-bib-0023){ref-type="ref"} After 8 hours of incubation, migrated cells were fixed and counted in images taken of randomly selected fields. The average number of cells was calculated from these images.

2.10. Dual‐luciferase assay {#cas13626-sec-0012}
---------------------------

Cells were cultured in 12‐well plates and transfected with luciferase constructs (9xCAGA‐luc). For normalization, pGL4.75‐CMV‐Renilla was co‐transfected. Cells were lysed and used for luciferase assay using the Dual‐Luciferase Reporter Assay System (Promega, Fitchburg, WI, USA). Data were collected using Mithras LB‐940 (Berthold Technologies, Bad Wildbad, Germany).

2.11. ChIP {#cas13626-sec-0013}
----------

Cells were cultured in 10‐cm plates, and ChIP was performed using anti‐Smad2/3 antibody. ChIP‐qPCR was performed as previously described.[22](#cas13626-bib-0022){ref-type="ref"} All samples were run in duplicate, and results were averaged. Primer sequences are shown in Table [S2](#cas13626-sup-0002){ref-type="supplementary-material"}.

2.12. RNA sequencing {#cas13626-sec-0014}
--------------------

Total RNA was extracted with the RNeasy Mini Kit (QIAGEN) from shRNA‐transfected A549 cells treated with TGF‐β for 24 hours. mRNA was purified using the Dynabeads mRNA DIRECT Purification Kit (Thermo Fisher Scientific). Libraries were prepared using the Ion Total RNA‐Seq Kit v2 according to the manufacturer\'s protocol and directionally sequenced with the Ion Proton (Thermo Fisher Scientific). Reads were aligned against the human genome (hg19) using TopHat2 (<https://ccb.jhu.edu/software/tophat/>). Differential expression was evaluated using the Cuffdiff function of Cufflinks (<http://cufflinks.cbcb.umd.edu/>). The raw sequencing data are available from Gene Expression Omnibus (GEO) (GSE109296).

2.13. Statistical analysis {#cas13626-sec-0015}
--------------------------

Comparisons between the multiple experimental groups were made using one‐way ANOVA with the Holm‐Sidak test. Statistical analyses were conducted with Prism 6.

3. RESULTS {#cas13626-sec-0016}
==========

3.1. *NORAD* regulates transforming growth factor‐β signaling and expression of epithelial‐to‐mesenchymal transition‐related genes {#cas13626-sec-0017}
----------------------------------------------------------------------------------------------------------------------------------

To better understand the function of *NORAD* in lung cancer cells, we performed RNA‐seq in *NORAD*‐silenced A549, a human lung adenocarcinoma cell line, in the presence of TGF‐β to induce EMT. We then conducted Gene Set Enrichment Analysis (GSEA) of the RNA‐seq data. We found that a gene set upregulated by TGF‐β and a gene set related to EMT, both from the Molecular Signatures Database (MSigDB), were enriched among the genes expressed in control cells compared to those expressed in *NORAD*‐depleted cells (Figure [1](#cas13626-fig-0001){ref-type="fig"}A,B). Moreover, the depletion of *NORAD* resulted in more marked changes when TGF‐β‐induced genes in A549 cells were used as the gene set (Figure [1](#cas13626-fig-0001){ref-type="fig"}C). The effect of *NORAD* knockdown on the expression of each gene is provided in Table [S3](#cas13626-sup-0002){ref-type="supplementary-material"}. We then reanalyzed published data (GSE79804) involving human osteosarcoma U2OS cells.[18](#cas13626-bib-0018){ref-type="ref"} The results of U2OS cells in which *NORAD* was overexpressed (Figure [S1](#cas13626-sup-0001){ref-type="supplementary-material"}A,B) and depleted (Figure [S1](#cas13626-sup-0001){ref-type="supplementary-material"}C,D) also indicated that *NORAD* positively regulates TGF‐β signaling and the EMT‐like phenotype. However, these data also suggested that the overexpression of PUM1 did not inhibit but rather enhanced TGF‐β signaling and EMT (Figure [S1](#cas13626-sup-0001){ref-type="supplementary-material"}E,F). We confirmed by RT‐PCR that the expression of TGF‐β target genes, including *SERPINE1* and *SNAI1*, was not significantly affected by overexpression of PUM1 in A549 cells, indicating that the function of *NORAD* in TGF‐β signaling and EMT is independent of Pumilio proteins (Figure [S2](#cas13626-sup-0001){ref-type="supplementary-material"}).

![*NORAD* upregulates the expression of genes related to transforming growth factor‐β (TGF‐β) signaling and EMT in lung adenocarcinoma cells. A,B, Gene expression data obtained by RNA‐seq in A549 cells expressing *NORAD*‐targeted shRNA were used for gene set enrichment analysis. An expression cutoff of fragments per kilobase of exon per million mapped sequence reads (FPKM) value ≥10 was applied for evaluation. A list of the top most enriched oncogenic signature (A) and hallmark gene sets (B) (MSigDB) and gene lists upregulated in the negative control (shNC) relative to *NORAD*‐knockdown (shNORAD\#1) cells are shown. The number of genes in each set, normalized enrichment score (NES), and false discovery rate (FDR) are shown for each gene set analyzed. (C) A gene set upregulated by TGF‐β in A549 cells was obtained from the RNA‐seq data, and the effect of *NORAD* knockdown on their expression levels was evaluated](CAS-109-2211-g001){#cas13626-fig-0001}

3.2. *NORAD* upregulates the transforming growth factor‐β‐Smad pathway {#cas13626-sec-0018}
----------------------------------------------------------------------

Next, we verified that the knockdown of *NORAD* did not affect the mRNA expression of *SMAD2* and *SMAD3* by RT‐PCR (Figure [2](#cas13626-fig-0002){ref-type="fig"}A). However, it was revealed that several TGF‐β‐induced target genes and EMT marker genes (*SERPINE1*,*SNAI1* and *FN1*) were significantly downregulated in *NORAD*‐depleted cells (Figure [2](#cas13626-fig-0002){ref-type="fig"}A). Of note, the expression of *CDH1* was downregulated by *NORAD* shRNA in the absence of TGF‐β, and the inhibitory effect of TGF‐β on *CDH1* expression was not affected by the presence of the shRNA, implying that *NORAD* affects some of the EMT phenotype in a TGF‐β‐independent manner. In contrast, stable overexpression of *NORAD* increased the expression of *SMAD2*, TGF‐β‐induced target genes and EMT marker genes (Figure [S3](#cas13626-sup-0001){ref-type="supplementary-material"}A). For further confirmation, luciferase reporter assays using 9xCAGA‐luc, a Smad3‐specific reporter,[24](#cas13626-bib-0024){ref-type="ref"} were performed in *NORAD*‐depleted A549 cells. The results showed that *NORAD* knockdown significantly suppressed the TGF‐β‐induced 9xCAGA reporter activity (Figure [2](#cas13626-fig-0002){ref-type="fig"}B). Consistently, forced expression of *NORAD* increased the TGF‐β‐induced Smad3‐specific luciferase reporter activity (Figure [S3](#cas13626-sup-0001){ref-type="supplementary-material"}B). We then performed ChIP‐qPCR analysis of Smad2/3. Depletion of *NORAD* reduced the enrichment of Smad2/3 in the *SERPINE1* and *ID1* promoter regions, although not statistically significant (Figure [2](#cas13626-fig-0002){ref-type="fig"}C). In contrast, *NORAD* shRNAs showed little effect on the TGF‐β‐induced C‐terminal phosphorylation of Smad2 and Smad3, indicating that *NORAD* regulates the activation of Smad signaling independently of their C‐terminal phosphorylation (Figure [2](#cas13626-fig-0002){ref-type="fig"}D).

![*NORAD* upregulates transforming growth factor‐β (TGF‐β)‐Smad signaling. A, A549 cells expressing the indicated shRNAs were treated with (+) or without (−) TGF‐β for 24 h. mRNA expression was quantified by quantitative RT‐PCR. Results are means ± **SE** of the means of 5 independent experiments. \*\**P *\< .01; \*\*\**P *\< .001. B, A549 cells expressing the indicated shRNAs were transfected with luciferase reporter construct (9xCAGA‐luc) and treated with (+) or without (−) TGF‐β for 24 h. Cells were harvested and assayed for luciferase activities. Results are means ± **SE** of the means of 5 independent experiments. \**P *\< .05; \*\**P *\< .01. C, ChIP‐qPCR was performed in A549 cells expressing the indicated shRNAs and treated with TGF‐β for 1 h. Results are means ±** SE** of the means of 5 independent experiments (*SERPINE1* and *ID1*). In the case of *HPRT1*, used as a negative control, standard deviations could not be calculated because some of the samples were below the detection limit. D, A549 cells were treated as in (A). Cells were then harvested for immunoblotting. The positions of the molecular weight markers are shown on the right](CAS-109-2211-g002){#cas13626-fig-0002}

3.3. *NORAD* is important for nuclear transport of the transforming growth factor‐β‐induced Smad complexes {#cas13626-sec-0019}
----------------------------------------------------------------------------------------------------------

We next focused on TGF‐β‐induced nuclear‐cytoplasmic translocation of the Smad complexes. Nuclear/cytoplasmic fractionation showed that in response to TGF‐β, total and phosphorylated Smad2 was found in the nuclear fraction, but in *NORAD*‐depleted cells, cytoplasmic phosphorylated Smad2 and Smad3 were increased and nuclear total and phosphorylated Smad2 and Smad3 were reduced (Figure [3](#cas13626-fig-0003){ref-type="fig"}A). Consistent with these findings, the results of immunostaining for Smad2 showed that depletion of *NORAD* partially inhibited TGF‐β‐induced nuclear staining of Smad2 protein (Figure [3](#cas13626-fig-0003){ref-type="fig"}B). These results indicate that *NORAD* affects the TGF‐β‐induced nuclear translocation of the Smad complexes.

![*NORAD* mediates transforming growth factor‐β (TGF‐β)‐induced nuclear transport of the Smad complexes. A, A549 cells expressing the indicated shRNAs were treated with (+) or without (−) to TGF‐β for 1 h. Cell lysates were fractionated into cytoplasmic and nuclear fractions, and immunoblotting was performed. The relative band intensities of the immunoblots of phosphorylated Smad2 and Smad3 (pSmad2 and pSmad3, respectively) after normalization with tubulin (cytoplasm) or HDAC1 (nucleus) are shown in the panel. The positions of the molecular weight markers are shown on the right. B, A549 cells were treated as in (A). Cells were then fixed and immunostained with the anti‐Smad2 antibody. Scale bar, 20 μm. C, A549 cells expressing the indicated shRNAs were transfected with expression plasmids for 6xMyc‐Smad3 and FLAG‐importin β1 and treated with TGF‐β for 1 h. Cell lysates were subjected to immunoprecipitation using an antibody against FLAG. Immunoprecipitates and 5% input extracts were immunoblotted with the antibodies against Smad3 or FLAG. The positions of the molecular weight markers are shown on the right](CAS-109-2211-g003){#cas13626-fig-0003}

Nuclear transport of the Smad complexes is regulated by several pathways, including importin‐mediated nuclear import.[2](#cas13626-bib-0002){ref-type="ref"}, [3](#cas13626-bib-0003){ref-type="ref"}, [4](#cas13626-bib-0004){ref-type="ref"} To determine the role of *NORAD* in regulating these pathways, we attempted to identify its interacting proteins by examining a list of proteins found in *NORAD* RNA co‐precipitates which were identified by mass spectrometry.[17](#cas13626-bib-0017){ref-type="ref"}, [18](#cas13626-bib-0018){ref-type="ref"} Interestingly, this suggested that *NORAD* interacts with importin 7 and importin β1, both of which have been reported to be important for the nuclear import of phosphorylated Smads.[2](#cas13626-bib-0002){ref-type="ref"}, [3](#cas13626-bib-0003){ref-type="ref"}, [4](#cas13626-bib-0004){ref-type="ref"} In particular, the results of co‐immunoprecipitation assay showed that knockdown of *NORAD* partially inhibited interactions between Smad3 and importin β1 in TGF‐β‐treated A549 cells (Figure [3](#cas13626-fig-0003){ref-type="fig"}C). Together, these results suggest that the cytoplasmic lncRNA *NORAD* is involved in the formation of Smad3 and importin β1 complexes, which is one of the crucial steps in the signal‐induced nuclear translocation of the Smad complexes.

3.4. *NORAD* mediates transforming growth factor‐β‐induced epithelial‐to‐mesenchymal transition‐like phenotype in lung adenocarcinoma cells {#cas13626-sec-0020}
-------------------------------------------------------------------------------------------------------------------------------------------

Finally, we explored the effects of *NORAD* knockdown on tumor cell motility using a chamber migration assay. Knockdown of *NORAD* significantly suppressed cell migration compared to that in control cells (Figure [4](#cas13626-fig-0004){ref-type="fig"}A). Because the remodeling of actin filaments is necessary for completing EMT, we then performed phalloidin staining to visualize filamentous actin (F‐actin) formation. The results revealed that TGF‐β induced actin stress fiber formation in control cells. In contrast, *NORAD*‐depleted cells showed reduced stress fiber formation and a rounder morphology (Figure [4](#cas13626-fig-0004){ref-type="fig"}B), indicating that *NORAD* affects actin cytoskeletal reorganization and EMT‐like morphological changes induced by TGF‐β in these cells.

![*NORAD* regulates cell migration and F‐actin formation. A, A549 cells expressing indicated shRNAs were treated with (+) or without (−) transforming growth factor‐β (TGF‐β) for 24 h. Cells were then seeded in upper chambers with collagen‐coated pores. Cells that migrated through the membrane were counted after 8 h of incubation. Representative fields are shown (left). Results are means ± SE of the means of 3 independent experiments (right). \*\*\**P *\< .001. B, A549 cells were treated as in (A). Cells were then fixed and stained with phalloidin--tetramethylrhodamine B isothiocyanate. Scale bar, 20 μm](CAS-109-2211-g004){#cas13626-fig-0004}

4. DISCUSSION {#cas13626-sec-0021}
=============

Epithelial‐to‐mesenchymal transition has been shown to play important roles in the invasion and metastasis of epithelial cancers including NSCLC. In NSCLC, it has been reported that EMT markers are highly expressed in tumor cells at the peripheral leading edge when compared with centrally located cells.[25](#cas13626-bib-0025){ref-type="ref"} The EMT phenotype is also frequently associated with therapeutic resistance in lung adenocarcinoma cells.[26](#cas13626-bib-0026){ref-type="ref"}, [27](#cas13626-bib-0027){ref-type="ref"} Taken together, EMT leads to aggressive tumor behavior in NSCLC and may represent a potential target for cancer therapy.

Epithelial‐to‐mesenchymal transition causes epithelial cells to lose polarity and acquire properties of mesenchymal cells. Previous studies have demonstrated that TGF‐β induces EMT in lung adenocarcinoma cells, including A549 cells.[28](#cas13626-bib-0028){ref-type="ref"}, [29](#cas13626-bib-0029){ref-type="ref"} TGF‐β directly induces the expression of the EMT transcription factors Snail, Slug, ZEB1, ZEB2, Twist and E12/E47. In addition, previous reports have indicated that some lncRNAs, including lncRNA‐ATB, ANCR, lncRNA‐HIT and MEG3,[12](#cas13626-bib-0012){ref-type="ref"}, [13](#cas13626-bib-0013){ref-type="ref"}, [14](#cas13626-bib-0014){ref-type="ref"}, [15](#cas13626-bib-0015){ref-type="ref"}, [16](#cas13626-bib-0016){ref-type="ref"} play roles in TGF‐β‐induced EMT and TGF‐β signaling. Here, we identified the lncRNA *NORAD* as a new regulator of TGF‐β signaling and EMT‐like phonotype. Notably, GSEA analysis revealed that *NORAD* induced EMT‐related genes, and regulation of the expression of *SERPINE1*,*SNAI1* and *FN*1 was confirmed by RT‐PCR. However, *NORAD* appears to regulate *CDH1* expression in a TGF‐β‐independent manner, suggesting that *NORAD* regulates some, but not all, the EMT‐related genes, in the process of EMT.

*NORAD*, a highly conserved lncRNA, has been reported to act as a negative regulator of Pumilio proteins,[17](#cas13626-bib-0017){ref-type="ref"}, [18](#cas13626-bib-0018){ref-type="ref"} the RNA‐binding post‐transcriptional repressors of the specific mRNAs, and it has also been implicated in tumor progression. In breast cancer cells, knockout of *NORAD* suppresses tumor cell growth and proliferation.[19](#cas13626-bib-0019){ref-type="ref"} In pancreatic cancer patients, *NORAD* upregulation is correlated with poor overall survival.[20](#cas13626-bib-0020){ref-type="ref"} The same study also showed that the depletion of *NORAD* inhibits hypoxia‐induced EMT and metastasis in vitro and in vivo in pancreatic cancers, in which *NORAD* probably acts as a competitive endogenous RNA (ceRNA) to regulate RhoA through competition with hsa‐miR‐125a‐3p. In colorectal cancer patients, the expression of *NORAD* is positively related with EMT, metastasis and poor prognosis through serving as a ceRNA for miR‐202‐5p.[30](#cas13626-bib-0030){ref-type="ref"} Here, we showed a different potential mechanism by which *NORAD* regulates EMT. Our results demonstrated that *NORAD* positively regulates TGF‐β signaling and TGF‐β‐induced EMT‐like phenotype in lung adenocarcinoma cells in a Pumilio‐independent manner. Because our results indicated that *NORAD* also affects TGF‐β signaling in U2OS cells, it may widely function as a regulator of TGF‐β signaling.

In the present study, we focused on the role of *NORAD* in the signal‐induced nuclear translocation of the Smad complexes, which is an essential step for TGF‐β signaling. According to previously published mass spectrometry data,[17](#cas13626-bib-0017){ref-type="ref"}, [18](#cas13626-bib-0018){ref-type="ref"} *NORAD* has the ability to bind to importin β1. Although one study showed that importin β1 interacts with Smad3 but not with Smad2, another group reported that knockdown of importin β1 abrogates nuclear import of both Smad2 and Smad3.[31](#cas13626-bib-0031){ref-type="ref"} The results of the immunoprecipitation assay showed that *NORAD* appears to affect the interaction between Smad3 and importin β1 (Figure [3](#cas13626-fig-0003){ref-type="fig"}C). Several cytoplasmic RNAs have been reported to interact with cytoplasmic proteins and modulate their roles.[32](#cas13626-bib-0032){ref-type="ref"}, [33](#cas13626-bib-0033){ref-type="ref"} *NORAD* may, thus, regulate the nuclear transport of the Smad complexes by affecting importin β1‐Smad3 interactions, although its precise molecular mechanism remains to be elucidated. Because there is no evidence that *NORAD* interacts with Smad3 or other Smad proteins, the effect of *NORAD* on interactions between importin β1 and Smad3 may be transient or indirect. Moreover, it has been shown that importin β1 recognizes nuclear localization signals and is involved in pathways other than TGF‐β signaling, such as the STAT3 and p53 pathways.[34](#cas13626-bib-0034){ref-type="ref"}, [35](#cas13626-bib-0035){ref-type="ref"} It is, therefore, possible that *NORAD* has broad roles in maintaining nuclear translocation and signal transduction. Further studies on the roles of *NORAD* in TGF‐β signaling and EMT will facilitate our understanding of lncRNA biology in cancer.
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